Sarepta Skyrockets on 48-Week Data

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

87.4 meters.

For Duchenne muscular dystrophy patients taking a 50 milligram dose of Sarepta Therapeutics' (Nasdaq: SRPT  ) eteplirsen for 48 weeks, that's how much longer the average patient walked during a six-minute walk test than a placebo group, which began taking the drug after 24 weeks. Not only did the 50mg group outperform placebo, but it showed an average 27.1 meter increase in distance walked over the treatment period -- an astonishing improvement over the 36-week data, which showed a 5.2 meter decline for the 50mg group. 

Not only did the walk test show a statistically significant benefit, but measures of dystrophin, a vital protein that protects muscle fibers, showed statistically significant increases in both the initial treatment and delayed treatment/placebo group.

This is the kind of data that could merit an accelerated approval from the Food and Drug Administration. We'll have to wait to find out for sure, but shareholders are already piling in, bidding up shares by more than 110% in early morning trading.

Foolish bottom line
One thing's for sure: These results are revolutionary for the patients and families dealing with Duchenne. However, today's move could place the company's market cap in excess of $700 million, and with some analysts estimating eteplirsen sales would reach about $500 million a year, it's unclear whether joining the crowd is a good idea at these levels. 

If you're looking for another revolutionary idea, I invite you to read about a trend our analysts are calling "The Next Trillion-Dollar Revolution." In this special free report, we outline a company, unlike Sarepta, that's flying under the radar as it participates in a massive global growth trend. Click here now to claim your copy.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2041739, ~/Articles/ArticleHandler.aspx, 10/23/2016 12:16:36 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
SRPT $47.98 Down -1.07 -2.18%
Sarepta Therapeuti… CAPS Rating: **